Land: Storbritannien
Sprog: engelsk
Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)
Benserazide hydrochloride; Levodopa
Roche Products Ltd
N04BA02
Benserazide hydrochloride; Levodopa
50mg ; 200mg
Oral capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04090100; GTIN: 5000471002041
1 uk-madopar-pl-clean-150817-62.5-125-250-hard capsules PACKAGE LEAFLET: INFORMATION FOR THE PATIENT UK MADOPAR 50 MG/12.5 MG ROCHE MADOPAR 100 MG/25 MG MADOPAR 200 MG/50 MG HARD CAPSULES Levodopa and benserazide (as hydrochloride) PLEASE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Madopar is and what it is used for 2. What you need to know before you take Madopar 3. How to take Madopar 4. Possible side effects 5. How to store Madopar 6. Contents of the pack and other information 1. WHAT MADOPAR IS AND WHAT IT IS USED FOR Madopar capsules contain two medicines called levodopa and benserazide. They are used to treat Parkinson’s disease. People with Parkinson’s disease do not have enough dopamine in certain parts of their brains. This can result in slow movements, stiff muscles and tremor. Madopar works like this: • In your body the LEVODOPA is changed into dopamine. Dopamine is the active medicine that is needed in your brain to help Parkinson’s disease. • The BENSERAZIDE allows more of the levodopa you take to get into your brain, before it is changed into dopamine. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MADOPAR DO NOT TAKE MADOPAR IF: • You are allergic (hypersensitive) to levodopa, benserazide or any of the other ingredients of Madopar (listed in Section 6: Contents of the pack and other information). • You have a problem with the pressure in your eyes called ‘narrow-angle glaucoma’. • You have serious problems with your kidneys, liver or heart. • You have a serious proble Læs hele dokumentet
OBJECT 1 MADOPAR 200MG/50MG HARD CAPSULES Summary of Product Characteristics Updated 17-Mar-2016 | Roche Products Limited 1. Name of the medicinal product Madopar 200 mg/50 mg Hard Capsules 2. Qualitative and quantitative composition Each capsule contains 200.0 mg Levodopa and 50 mg Benserazide (as benserazide hydrochloride). For excipients, see section 6.1 3. Pharmaceutical form Capsules, hard. Light brown opaque body and a powder blue opaque cap, imprinted with the name 'Roche' in black ink on both sides. 4. Clinical particulars 4.1 Therapeutic indications Parkinsonism - idiopathic post-encephalitic. Previous neurosurgery is not a contra-indication to Madopar. 4.2 Posology and method of administration Dosage and administration are variable and no more than a guide can be given. _ADULTS_ _PATIENTS NOT PREVIOUSLY TREATED WITH LEVODOPA_ The recommended initial dose is one capsule or dispersible tablet of Madopar 50 mg/12.5 mg three or four times daily. If the disease is at an advanced stage, the starting dose should be one capsule or dispersible tablet of Madopar 100 mg/25 mg three times daily. The daily dosage should then be increased by one capsule or dispersible tablet of Madopar 100 mg/25 mg, or their equivalent, once or twice weekly until a full therapeutic effect is obtained, or side-effects supervene. In some elderly patients, it may suffice to initiate treatment with one capsule or dispersible tablet of Madopar 50 mg/12.5 mg once or twice daily, increasing by one capsule or dispersible tablet every third or fourth day. The effective dose usually lies within the range of four to eight capsules or dispersible tablets of Madopar 100 mg/25 mg (two to four capsules of Madopar 200 mg/50 mg) daily in divided doses, most patients requiring no more than six capsules or dispersible tablets of Madopar 100 mg/25 mg daily. Optimal improvement is usually seen in one to three weeks but the full therapeutic effect of Madopar may not be apparent for some time. It is advisable, therefore, to allow several weeks to elapse be Læs hele dokumentet